Long-term vagal stimulation for heart failure: Eighteen month results from the NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) trial
Language English Country Netherlands Media print-electronic
Document type Journal Article, Randomized Controlled Trial
PubMed
28663046
DOI
10.1016/j.ijcard.2017.06.036
PII: S0167-5273(17)31295-0
Knihovny.cz E-resources
- Keywords
- Autonomic modulation, Heart failure, Neural therapy, Parasympathetic nervous system, Vagal nerve stimulation, Vagus nerve,
- MeSH
- Time Factors MeSH
- Electrocardiography, Ambulatory mortality trends MeSH
- Middle Aged MeSH
- Humans MeSH
- Survival Rate trends MeSH
- Follow-Up Studies MeSH
- Aged MeSH
- Heart Failure diagnosis mortality therapy MeSH
- Vagus Nerve Stimulation mortality trends MeSH
- Treatment Outcome MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Randomized Controlled Trial MeSH
BACKGROUND: The NECTAR-HF study evaluated safety and feasibility of vagal nerve stimulation (VNS) for the treatment of heart failure patients. The first six-month randomized phase of the study did not show improvement in left ventricular remodelling in response to VNS. This study reports the 18-month results and provides novel findings aiming to understand the lack of efficacy of VNS, including a new technique assessing the effects of VNS. METHODS: Ninety-six patients were randomized 2:1 to active or inactive VNS for 6months, thereafter VNS was activated for all patients. The primary safety endpoint was 18-month all-cause mortality. RESULTS: Ninety-one patients continued in the long-term evaluation with active VNS. The on-therapy survival estimate at 18months was 95% with a 95% one-sided lower confidence limit of 91%, (better than the predefined criterion). Left ventricular systolic volume decreased in the crossover group (VNS OFF→ON; 144±37 to 139±40, p<0.05) after VNS activation; LVESD (5.02±0.77 to 4.96±0.82, p>0.05) and LVEF (33.2±4.9 to 33.3±6.5, p>0.05) did not change. A new technique to detect subtle heart rate changes during Holter recordings, i.e. "heat maps", revealed that VNS evoked heart rate response in only 13/106 studies (12%) at 6 and 12months with active VNS. CONCLUSIONS: Although a favourable long-term safety profile was found, improvements in the efficacy endpoints were not seen with VNS. A new technique for detecting acute heart rate responses to VNS suggests that the recruitment of nerve fibres responsible for heart rate changes were substantially lower in NECTAR-HF than in pre-clinical models.
Azienda Ospedaliera dei Colli Monaldi Napoli Italy
Boston Scientific Corporation St Paul MN United States
Department of Cardiology Catharina Hospital Eindhoven The Netherlands
Department of Cardiology Homolka Hospital Prague Czech Republic
Department of Cardiology Liverpool Heart and Chest Liverpool UK
Department of Cardiology University Medical Center Utrecht The Netherlands
Division of Cardiology Otto von Guericke Universität Magdeburg Germany
References provided by Crossref.org